ERBB2 and breast cancer: In a related finding, in a phase 2 trial of 23 patients with metastatic HER2+ BC, the combination of paclitaxel, trastuzumab, and dasatinib (Src inhibitor) showed high efficacy and success rate[80] [Table 1].